Lab to Lives

Send us Fan Mail Ever imagined the immense potential that decentralized clinical trials (DCTs) could unlock for patients and sponsors? This week, we're going on a deep dive into the world of DCTs with our esteemed guest, Ewa Lindqvist, a trailblazer in this space. Brace yourself for an enlightening conversation about how DCTs are paving the way for increased access to new treatments and real-...

Send us Fan Mail Prepare to uncover the transformative potential of open source software in the pharmaceutical industry! Our distinguished guest, Katja Glass, an influential open source ambassador, joins us on this enlightening journey. We'll explore the rising popularity of open source solutions in the pharmaceutical industry, its myriad benefits, and the profound impact of sharing tools, pr...

Send us Fan Mail Imagine being given a shot at a cure before it's even approved. That's the fascinating world of expanded access programs for unapproved investigational interventions that we're exploring today with our esteemed guest, Patti Zettler, law professor and chair of the International Society for Cell and Gene Therapies Expanded Access Working Group. We delve into the histo...

Send us Fan Mail Imagine you're on an eight-year journey trying to diagnose an autoimmune disease. Suzaan Sauerman, our insightful guest today, faced this exact challenge. Sauerman, a visionary in female representation in clinical trials, uncovers the persistent gender gap in this field and posits an innovative solution—wearable technology. We dig into the heart of Sauerman's story with...

Send us Fan Mail Let's face it, executive turnover in the life sciences industry is a conundrum. Companies are offering competitive compensation, fostering positive work cultures, and providing opportunities to contribute to meaningful work, yet many executives continue to leave. In our intriguing dialogue with the insightful Federico Grayeb, we delve into why this is happening and how job em...

Send us Fan Mail This week we speak to Ravi Samavedam, Chief Innovation Officer for Azzur Group, about how on demand clean rooms can transform the business model for biotechs.  We start out by exploring what the standard two choices biotech’s typically have for clinical trial manufacturing: Building their own infrastructure Outsourcing to a contract manufacturing organization Both options have pro...

Send us Fan Mail This week we speak to Leif Kuse , who is Lead Trailblazer of Drug Development Outsourcing Disruption and CEO PHARALL. We speak about group purchasing for biotechs in clinical trials . We start out by exploring how CRO contracting usually happens for biotechs, where clinical trials are typically outsourced to CROs.  Biotech outsourcing is especially tricky, because in especially sm...

Send us Fan Mail This week we speak to Tirrell Payton, Managing Partner at Nooma Group Consulting, about mindset in life sciences.  We speak about how there is a disconnect between the level of risk willingness among the top levels in organizations and middle managers. Middle managers are often afraid to make a mistake - and become the “permafrost layer” where change has a tough time to take root....

Send us Fan Mail This week we speak to Philip Russmeyer, Founder & CEO of Fitfile, about the promises that true data anonymization holds for transforming clinical trials.  We dive into the differences between t okenization, anonymization and pseudonymisation of data. And how the difference is whether individuals can ever be identified or if the data is masked with a token that can potentially...

Send us Fan Mail This week we host Sam Ewing, who is the Global Head of Pharma Partnerships at Doccla. We speak about endpoint development in general - and digital endpoint development in particular.  We define digital endpoints as something that happens in a patient's home, and is mediated by a smartphone with some technology associated with it.  The benefits of digital endpoints for patient...

Send us Fan Mail This week we host Christian Born Djurhuus, who is a physician by training, a self-proclaimed geek and has had an impressive career in life sciences in the intersections between drug development, leadership and technology.  We speak about how the waterfall mentality is prevalent in life sciences, where specifications are developed by one group and tossed over the fence to the next...

Send us Fan Mail This week we speak to Simon Taylor, Head of European Solutions Consulting at Florence Healthcare. We focus on site oriented technology transformation.  We speak about the current challenges that clinical sites face , such as the high degree of churn within the healthcare industry, the increasing complexity of protocols and the prevalence of paper as the primary recording mechanism...

Send us Fan Mail This week we speak to Ole Henriksen, Associated Partner of Nordic Healthcare Group and pharmaceutical market access expert. We speak about how health technology assessments (HTA) has impacted how we conduct clinical trials.  Health Technology Assessment (HTA) emerged first as a research area in decision aids. Later, during the 1990s, as a formal requirement for reimbursement. Due...

Send us Fan Mail This week we are hosting Kimberly Tableman, Founder and CEO of ESPERO Health, and speak about how clinical trial protocols are being re-imagined in our industry. We dive into what a protocol actually is and what it describes.  Protocols are currently being developed with a lot of manual research . WIth googling, phoning friends and re-using existing protocols in word documents.  T...

Send us Fan Mail This week we have André Chagwedera in the studio, the Founder and CEO of Fleming Protocol. We focus on health data, and what it would mean for patients to own their data.  One of the consequences of patients owning their data would be that patient communities would have a say in which areas to conduct clinical research in as well as the design of clinical protocols. Fleming Protoc...

Send us Fan Mail We speak to Raj Indupuri, the co-founder & CEO of eClinical Solutions, about why data plays such a key role in our industry. And dispute this being true for as long as we have had clinical trials, the recent technological advancements open up the possibilities for true data-driven decision making.  Even though the clinical space has been digitising for many years, d igitizatio...

Send us Fan Mail Today we speak with Lars Rosendal , the VP of Global Clinical Operations at LEO Pharma. We speak about how clinical development is an innovation game - and how both governments and patients are willing to pay for innovation. Patients in many major diseases are well served. That means we need to push the innovation to bring something to market that is either much safer, or has a hi...

Send us Fan Mail In this episode we speak to Rebecca Godfrey, the author of The Leadership Vaccine, about transforming specialists into leaders. In The Leadership Vaccine we follow a story of how a company transforms itself - and discovers the five pillars of leadership. We speak about how the state of leadership in life sciences is improving as the science of leadership is gaining a more prominen...

Send us Fan Mail  Today is World Rare Disease day. It is only fitting that we speak to Sophia Zilber who is a statistical programmer, but also Board Member & Director of Patient Registries at the Cure MITO Foundation, about bridging the gap between the life sciences industry and patient registries in rare diseases .  Sophia has experienced first hand how rare diseases lack both data and fundin...

Send us Fan Mail We speak to Johan Lauritsen, CEO & Founder of Probe, about how clinical trials can be an alternative to treatment.  Johan himself tried to enrol in a clinical trial for his rare chronic disease. This was an uphill battle and he never succeeded - but the experience did kindle his desire to make clinical trials available for patients. Enrolling in a trial for a patient is not ea...

Send us Fan Mail We speak to Maya Zlatanova , the CEO and Founder of Trialhub and FindMeCure about trial strategy for clinical trials. We speak about the amount of information necessary to digest in order to answer the many complex questions during trial start-up, and how starting from the templates of previous trials can both be time-saving, but may also limit your perspective on what is possible...

Send us Fan Mail This week we speak to Dr. Daniel Fox, founder & CEO of Clinical Research Payment Network about how the power dynamic between sponsors and sites is shifting. We speak about the harms of “talkdown tech” and how sites can take back control over their own processes.     We speak about the predominant model today and how sponsors in the name of efficiency introduce systems and proc...

Send us Fan Mail This week we speak to Brian D Smith , professor and author of a brand new book New Drugs, Fair Prices. In the book and on the show Brian suggests that we can have our cake and eat it too - meaning that we can have fair drug prices, yet still encourage pharmaceutical innovation.  Brian talks us through what it means to apply a generalised Darwinian approach to the life sciences eco...

Send us Fan Mail We speak to Graham Dutfield, professor of International Governance and author of That High Design of Purest Gold on the evolution of IP regulation in Pharma and how it could be transformed in the future.    Patents are a historic tool, but have undergone an evolution. Patents started out in the 1470’s in Venice, and as an example Christoffer Columbus had a patent to explore the ne...

Send us Fan Mail This week we dive into pharmacometrics as a discipline and the potential for replacing and augmenting clinical trials with modelling. We speak to Kristin Carlsson Petri, who is a Director of Pharmacometrics.    Pharmacometrics modelling is a range of mathematical modelling techniques that can quantify our knowledge of drug biology and disease as well as trial information. The powe...